Cantor Fitzgerald Weighs in on ACRV FY2026 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Acrivon Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($1.89) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share.

ACRV has been the topic of a number of other research reports. HC Wainwright lowered their price target on Acrivon Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Oppenheimer lowered their price target on Acrivon Therapeutics from $10.00 to $9.00 and set an “outperform” rating on the stock in a report on Thursday, May 15th. Piper Sandler initiated coverage on Acrivon Therapeutics in a report on Monday, May 5th. They set an “overweight” rating and a $6.00 price target on the stock. Finally, Jones Trading reissued a “hold” rating on shares of Acrivon Therapeutics in a report on Friday, May 16th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $17.71.

Acrivon Therapeutics Price Performance

NASDAQ ACRV opened at $1.27 on Wednesday. Acrivon Therapeutics has a 52-week low of $1.05 and a 52-week high of $10.16. The business’s 50-day moving average price is $1.39 and its 200 day moving average price is $4.14. The firm has a market cap of $39.82 million, a P/E ratio of -0.47 and a beta of 1.56.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.06.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ACRV. Acorn Capital Advisors LLC acquired a new stake in shares of Acrivon Therapeutics during the 4th quarter valued at approximately $2,440,000. Wealthedge Investment Advisors LLC lifted its position in shares of Acrivon Therapeutics by 420.1% during the 1st quarter. Wealthedge Investment Advisors LLC now owns 56,467 shares of the company’s stock valued at $115,000 after acquiring an additional 45,610 shares during the period. Invesco Ltd. purchased a new position in shares of Acrivon Therapeutics during the 1st quarter worth approximately $72,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Acrivon Therapeutics by 29.7% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock worth $619,000 after purchasing an additional 23,535 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in Acrivon Therapeutics in the 1st quarter valued at approximately $27,000. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Acrivon Therapeutics

In other news, major shareholder Perceptive Advisors Llc sold 215,283 shares of Acrivon Therapeutics stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $1.56, for a total transaction of $335,841.48. Following the completion of the sale, the insider now directly owns 4,090,906 shares in the company, valued at approximately $6,381,813.36. This trade represents a 5.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 1,707,833 shares of company stock worth $3,009,858 over the last 90 days. Company insiders own 11.90% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.